



Fiscal Note
4th Sub. H.B. 389 (Green)
 2026 General Session
 Cannabis Amendments
 by Dailey-Provost, Jennifer
 (Vickers, Evan J.)



General, Income Tax, and Uniform School Funds

JR4-4-101

	Ongoing	One-time	Total
Net GF/ITF/USF (rev.-exp.)	\$0	\$0	\$0

State Government

UCA 36-12-13(2)(c)

Revenues	FY 2026	FY 2027	FY 2028
Dedicated Credits Revenue	\$0	\$43,400	\$43,400
Dedicated Credits Revenue, One-time	\$0	\$35,000	\$0
Qualified Production Enterprise Fund	\$0	\$2,413,900	\$2,413,900
Total Revenues	\$0	\$2,492,300	\$2,457,300

Enactment of this legislation could increase revenue to the Qualified Patient Enterprise Fund by \$2,413,900 ongoing beginning in FY 2027 from authorizing the collection of a uniform transaction fee on medical cannabis sales. Enactment of this legislation could also increase Dedicated Credit revenue to the Attorney General's Office by \$35,000 one-time and by \$43,400 ongoing beginning in FY 2027 to accommodate moving programs across agencies and to support the expanded responsibilities of the Specialized Product Authority Licensing Board.

Expenditures	FY 2026	FY 2027	FY 2028
Dedicated Credits Revenue	\$0	\$43,400	\$43,400
Dedicated Credits Revenue, One-time	\$0	\$35,000	\$0
Qualified Production Enterprise Fund	\$0	\$2,413,900	\$2,413,900
Total Expenditures	\$0	\$2,492,300	\$2,457,300

Enactment of this legislation could increase expenditures by the Department of Agriculture and Food by \$2,413,900 annually beginning in FY 2027 from the Qualified Production Enterprise Fund for staff, legal services, and enforcement in the specialized product division. Enactment could also shift Qualified Patient Enterprise Fund expenditures by \$1,646,400 one-time in FY 2026 and \$4,599,200 ongoing beginning in FY 2027 from the Department of Health and Human Services to the Department of Agriculture and Food (UDAF) from moving the medical cannabis program responsibilities in Title 26B to UDAF. Enactment of this legislation could also increase Dedicated Credit expenditures by the Attorney General's Office by \$35,000 one-time and by \$43,400 ongoing beginning in FY 2027 to accommodate moving programs across agencies and to support the expanded responsibilities of the Specialized Product Authority Licensing Board. Finally, enactment could increase expenditures from the Qualified Patient Enterprise Fund for the Center for Medical Cannabis Research (Center) by up

to \$1,250,000 per year beginning in FY 2027. Actual expenditures by the Center will depend on the balance of the fund and the determination by UDAF that there are sufficient revenues to authorize a transfer.

	<i>FY 2026</i>	<i>FY 2027</i>	<i>FY 2028</i>
Net All Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>

Local Government

UCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct, measurable costs for local governments.

Individuals & Businesses

UCA 36-12-13(2)(c)

Enactment of this legislation could cost medical cannabis patients \$2,413,900 ongoing beginning in FY 2027 from paying an additional uniform transaction fee on medical cannabis purchases.

Regulatory Impact

UCA 36-12-13(2)(d)

Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.

Performance Evaluation

JR1-4-601

This bill does not create a new program or significantly expand an existing program.

Notes on Notes

Fiscal explanations estimate the direct costs or revenues of enacting a bill. The Legislature uses them to balance the budget. They do not measure a bill's benefits or non-fiscal impacts like opportunity costs, wait times, or inconvenience. A fiscal explanation is not an appropriation. The Legislature decides appropriations separately.